- In April 2025, AstraZeneca, in collaboration with health-tech company Qure.ai, announced the successful completion of 5 million AI-enabled chest X-rays across over 20 countries in Asia, the Middle East, Africa, and Latin America. This initiative, part of AstraZeneca's commitment to the World Economic Forum's EDISON Alliance 1 Billion Lives Challenge, demonstrates the potential of AI to enhance lung cancer detection, particularly in resource-limited healthcare environments. The AI-enabled CXRs identified high-risk lung nodules in nearly 50,000 individuals, leading to further testing and potential diagnosis. This collaboration emphasizes the cost-effectiveness of AI as a triaging tool before low-dose CT scans (LDCT) and supports its integration into national health systems
- In May 2025, South Korean company Coreline Soft's flagship product, AVIEW LCS, an AI-powered lung cancer screening analysis software, has been added to Bayer's vendor-neutral, cloud-based marketplace for medical AI solutions, Calantic. This inclusion allows Coreline Soft to expand its reach, supplying its software to governments and hospitals across Europe, including an exclusive supply deal with the German government for its lung cancer screening trial, HANSE. This move signifies the growing trend of integrating specialized AI solutions into broader medical imaging platforms
- In April 2025, University Hospitals Cleveland Medical Center partners with Qure.ai for AI-enhanced lung cancer detection. A new collaboration between University Hospitals Cleveland Medical Center and Qure.ai focuses on deploying the FDA-cleared artificial intelligence (AI) qXR-LN for early lung cancer detection via chest X-rays. This AI tool acts as a "second read" for radiologists, aiming to improve the detection of subtle lung nodules. A prospective, randomized, control trial is underway to further assess and validate the AI's effectiveness in a real-world setting, highlighting the industry's commitment to rigorous validation of AI tools
- In July 2024, Bon Secours Mercy Health collaborates with Koninklijke Philips N.V. to enhance clinical workflows. This collaboration aims to improve clinical workflows through integrated solutions, including advanced imaging technologies and analytics platforms specifically designed for lung cancer detection. Such partnerships underscore the ongoing efforts to create comprehensive and efficient systems for early diagnosis and management of lung cancer
- In June 2024, UC Davis Health deploys new 3D CT imaging system for earlier lung cancer diagnosis. UC Davis Health became the first in its region to utilize a new mobile 3D CT imaging system, the Cios Spin by Siemens Healthineers, paired with Intuitive's robotic-assisted bronchoscopy system, Ion. This innovative combination allows for more precise biopsies by pinpointing potentially cancerous growths with real-time 3D images, addressing the challenge of lung movement during biopsies. This development signifies a focus on improving the accuracy and safety of diagnostic procedures
